Indication: Advanced Malignancies
An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) in subjects with advanced cancer
Sub-indication: Miscellaneous Malignancies
Study Type: Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Sponsor: Vincerx Pharma, Inc
Email for more information: MISC-NCIResearch@Nortonhealthcare.org Heme-NCIResearch@nortonhealthcare.org